PatientsVille.com LogoPatientsVille.com

Parkinson's Disease | Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients

Parkinson's Disease research study

What is the primary objective of this study?

Use lay language. Many decisions involve the possibility of gaining or losing relative to the status quo. The loss aversion behaviour is a cognitive concept explaining that people are more sensitive to the possibility of losing objects or money than they are to the possibility of gaining the same objects or amounts of money. We hypothesised that dopamine could be involved in the loss aversion behaviour. To highlight this, we have chosen a model of dopaminergic depletion : the Parkinson's disease The primary purpose of this protocol is to study the role of dopamine in the loss aversion phenomenon by comparing brain activity in parkinsonian patient with and without treatment with L Dopa, when they are exposed to mixed (gain/loss) gambles using money. The second purpose is to highlight the role of a dopamine depletion by comparing patient without treatment vs healthy paired control. 2 groups : - 20 parkinsonian patients (tested two times : with and without treatment by L dopa) - 20 healthy paired control Description of the protocol for patients : J0 : Inclusion visit (duration : 4h): - motor assessment (UPDRS) - neuropsychological and psychiatric assessment (MMS, MATTIS, BREF, Stroop, Ardouin scale, UPPS, MADRS, Hamilton, LARS). J0+1 day and J0 +2 days : 2 visits of MRI (magnetic resonance imaging) acquisition (with or without treatment) : Each acquisition was composed by an orientation sequence+ an anatomic sequence + a functional sequence. For healthy subjects, they have only one visit of 2 hours including a MMS, a MADRS and the MRI acquisitions.

Who is eligible to participate?

Inclusion Criteria: - Patients : - Men or women aged between 35 -75 years - Patients with an idiopathic Parkinson's disease according to UKPDSBB criterias with a disease evolution duration : 5-10 years) - With fluctuations in end of doses + morning akinesia. - Non dement (MMS>24 ; Mattis > 130) - Affiliated to National Health system - Having given their informed consent Healthy controls - Men or women aged between 35 to 75 years - Non dement (MMS>24 ) - Affiliated to National Health system - Having given their informed consent Exclusion Criteria: - Patients : - Patients suffering of an atypical Parkinson syndrome - Psychiatric pathology - Tremor form (≥ 3 (item tremor of UPDRS)) - Patients with Impulsive control disorders - Depression, dementia - Pregnant - Under guardianship - In excluding period for another study - Any contra-indication to MRI Healthy subject - Subject with neurological, psychiatric diseases - Depression, dementia - Pregnant - Under guardianship - In excluding period for another study - Any contra-indication to MRI

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Parkinson's Disease

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Behavioral:Role of dopamine

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

patients with and without treatment by L dopa)to study the role of dopamine in the loss aversion phenomenon by comparing brain activity in parkinsonian patient with and without treatment with L Dopa, when they are exposed to mixed (gain/loss) gambles using money.

healthy paired controlto highlight the role of a dopamine depletion by comparing patient without treatment vs healthy paired control.

Study Status

Unknown status

Start Date: March 2013

Completed Date: December 2015

Phase: Phase 4

Type: Interventional

Design:

Primary Outcome: percentage of signal modification

Secondary Outcome: Cluster activation size

Study sponsors, principal investigator, and references

Principal Investigator: Ulla MIGUEL

Lead Sponsor: University Hospital, Clermont-Ferrand

Collaborator:

More information:https://clinicaltrials.gov/show/NCT01780467

Discuss Dopamine